UBS Downgrades Auxilium Pharmaceuticals (AUXL) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Stifel Nicolaus Downgrades Auxilium Pharmaceuticals (AUXL) to Hold
September 22, 2014 6:48 AM EDTStifel Nicolaus downgraded Auxilium Pharmaceuticals (NASDAQ: AUXL) from Buy to Hold.
For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.
Shares of Auxilium Pharmaceuticals closed at $31.14 yesterday.
... MoreGoldman Sachs Downgrades Auxilium Pharmaceuticals (AUXL) to Neutral
September 19, 2014 7:29 AM EDTGoldman Sachs downgraded Auxilium Pharmaceuticals (NASDAQ: AUXL) from Buy to Neutral.
Analyst Gary Nachman said, "We downgrade AUXL to Neutral from Buy after ENDPs 9/16 offer to acquire AUXL for $28.10/share,... More
Endo's (ENDP) $2.2B Bid Undervalues Auxilium (AUXL) - Aegis Capital
September 17, 2014 9:01 AM EDTAegis Capital comments on Auxilium Pharma (Nasdaq: AUXL) following a $28.10 per share bid placed by Endo Pharma (Nasdaq: ENDP) on Tuesday night.
Analyst Raghuram Selvaraju commented, In our view, Endo is being opportunistic in the context of Auxilium's recent operational struggles, which began with the attrition seen in the testosterone... More
Auxilium (AUXL) Could Be Worth Up to $45/Share in a Potential Takeover - Jefferies
September 17, 2014 7:39 AM EDTJefferies analyst Thomas Wei weighed in on Auxilium Pharmaceuticals (NASDAQ: AUXL) after Endo offered to acquire the company for $28.10 per share. Wei sees more... More
Auxilium Pharma (AUXL) to Review Endo (ENDP) Bid; Adopts Poison Pill Provision
September 17, 2014 7:01 AM EDTAuxilium Pharma (NASDAQ: AUXL) confirmed that Auxilium has received an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ENDP) to acquire all of the outstanding shares of Auxilium common stock at a price of $28.10 per share in cash and Endo stock, subject to due diligence, financing and other conditions. A copy of the unsolicited, non-binding proposal that Auxilium received from Endo on Friday evening is reproduced below. Click here to view the letter.
Consistent with its fiduciary duties and in accordance with its existing merger agreement with QLT... More
